XERS

Xeris Biopharma Holdings, Inc.

Healthcare
Biotechnology
$1.95B market cap

Forecast run · Nov 4, 2026Upside rank 1428 of 3,184

Model Signal

ForecastQ Daily Probabilities

34.2%

36.4%

16.2%

Analyst Consensus

Recommendation2.09/5 Buy

Last price$10.71

Price target$15.00

Implied move+40.1%

Analysts11

ForecastQ Portfolios

XERS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.